Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEGACY aspirin omission study in NSTE-ACS after PCI
NL-OMON59311Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in acute coronary syndrome (ACS), sponsored by Amsterdam University Medical Center. Primary endpoints: Major or minor bleeding and Composite ischemic outcome. Started May 2022; status: active, not recruiting.
02
Drugs
aspirin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NL-OMON59311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59311.